WASHINGTON (AP) — The maker of a drug for Lou Gehrig’s disease that recently failed in a large study said Thursday it will pull the medicine from the market, acknowledging it didn’t help patients with the deadly neurological condition.
Amylyx Pharmaceuticals announced it will voluntarily halt sales and marketing of the drug in the U.S. and Canada, where new patients will no longer be able to get a prescription.
“While this is a difficult moment for the ALS community, we reached this path forward in partnership with the stakeholders who will be impacted and in line with our steadfast commitment to people living with ALS,” company co-founders said in a statement. Patients already taking the therapy who wish to continue will be able to enroll in a program to receive it for free.
The Food and Drug Administration approved the much-debated drug, Relyvrio, in September 2022, following a years-long advocacy campaign by patients with amyotrophic lateral sclerosis, or ALS.
Related articles:
Related suggestion:
Security footage appears to show that Alaska man did not raise gun before being killed by policePutin visits Harbin Institute of TechnologyStars center Roope Hintz out for Game 6 with upperCanadian police link 4 women killed in the 1970s to dead American serial sex offenderXi, Putin attend opening ceremony of ChinaRussia vows retaliation for Ukrainian strikes on its regionsFlorida State asks the NCAA to reduce and rescind penalties imposed on its football programSlovak PM in 'very serious' condition after being shotAI, digital technologies inject new impetus to cultural tourism boomChina ready to work with Arab countries for higher level community with shared future: Xi
3.2709s , 6496.265625 kb
Copyright © 2024 Powered by Why Amylyx is pulling ALS drug Relyvrio from US market after study ,World Weaver news portal